Candida glabrata: Review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans

Clinical Microbiology Reviews

Volumn 12, Issue 1, 1999, Pages 80-96

  Fidel Jr , Paul L ^a   Vazquez, Jose A ^b   Sobel, Jack D ^b  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BORIC ACID; BUTOCONAZOLE; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PYRROLE; TERCONAZOLE;

ADVERSE DRUG REACTION; ANIMAL MODEL; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDIASIS; COMPARATIVE STUDY; ESOPHAGUS DISEASE; HOST RESISTANCE; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUTH INFECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PHARYNX DISEASE; REVIEW; SYSTEMIC DISEASE; TOPICAL DRUG ADMINISTRATION; VAGINITIS; VIRULENCE;

EID: 0344923836     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/cmr.12.1.80     Document Type: Review

References (186)

1. Abi-Said, D. E., O. Uzon, I. Raad, H. Pinzcowski, and O. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128.
2. Anaissie, E. J., R. O. Darouiche, D. Abi-Said, O. Uzum, J. Mera, L. O. Gentry, T. Williams, D. P. Kontoyiannis, C. L. Karl, and G. P. Bodey. 1996. Management of invasive candidial infections: result of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. 23:964-972.
3. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, and T. Horan. 1991. Secular trends in nosocomial primary blood stream infections in the United States. Am. J. Med. 91:86S-89S.
4. Barns, S. M., D. J. Lane, M. L. Sogin, C. Bibeau, and W. G. Weisburg. 1991. Evolutionary relationships among pathogenic Candida species and relatives. J. Bacteriol. 173:2250-2255.
5. Barret-Bee, K., Y. Hayes, R. G. Wilson, and J. F. Ryley. 1985. A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. J. Gen. Microbiol. 131:1217-1221.
6. Bastide, M., M. Mallie, B. Montes, and J. M. Bastide. 1989. The epidemiology of hematogenous candidiasis caused by different Candida species. Pathol. Biol. 37:694-699.
7. Beck-Sague, C. M., and T. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States. J. Infect. Dis. 167:1247-1251.
8. Bendel, C. M., and M. K. Hostetter. 1991. Correlation of adhesion and pathogenic potential in yeast. Pediatr. Res. 29:167A. (Abstract.)
9. Bennett, J. E. 1978. Diagnosis and management of candidiasis in the immunocompromised host. Scand. J. Infect. Dis. Suppl. 16:83-86.
10. Bennett, J. E. 1990. Antimicrobial agents: antifungal agents, p. 1165-1181. A. G. Gilman, T. W. Rall, A. S. Nies, and P. Taylor (ed.), Goodman and Gilman's the pharmacological basis of therapeutics. Pergamon Press, Inc., Elmsford, N.Y.
11. Bodey, G. P. 1986. Candidiasis in cancer patients. Am. J. Med. 77:13-19.
12. Boerlin, P., F. Boerlin-Petzold, J. Goudet, C. Durussel, J. Pagani, J. Chave, and J. Bille. 1996. Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting. J. Clin. Microbiol. 35:1235-1248.
13. Brawner, D. L., and J. E. Cutler. 1984. Variability in expression of a cell surface determinant on Candida albicans as evidenced by an agglutinating monoclonal antibody. Infect. Immun. 43:966.
14. Bross, J., G. H. Talbot, G. Maislin, S. Hurwitz, and B. L. Strom. 1989. Risk factors for nosocomial candidemia a case control study in adults without leukemia. Am. J. Med. 87:614-620
15. Cantorna, M. T., and E. Balish. 1990. Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect. Immun. 58:1093-1100.
16. Cartledge, J. D., J. Midgley, and B. G. Gazzard. 1997. Itraconazole cyclodextrin solution: the role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidosis. AIDS 11:163-168.
17. Cassone, A., F. DeBernardis, F. Mondello, T. Ceddia, and L. Agatensi. 1987. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J. Infect. Dis. 156:777-783.
18. Cauwenbergh, G. 1990. Vaginal candidiasis: evolving trends in the incidence and treatment of non-Candida albicans infections. Curr. Probl. Obstet. Gynecol. Fertil. 8:241-245.
19. Chakrabarti, A., N. Nayak, and P. Talwar. 1991. In vitro proteinase production by Candida species. Mycopathologia 114:163-168.
20. Clark, R. A., S. A. Blakley, J. Rice, and W. Brandon. 1995. Predictors of HIV progression in women. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 9:43-50.
21. Coker, R. J., M. Fisher, and D. R. Tomlinson. 1995. Management of mycoses associated with HIV disease. Int. J. STD AIDS 6:408-412.
22. Coppola, S., G. Angarano, M. T. Montagna, P. Congedo, L. Monno, A. Bellisario, and G. Pastore. 1995. Efficacy of itraconazole in treating AIDS-associated infections due to Candida krusei. Eur. J. Epidemiol. 11:243-244.
23. DeBernardis, F., L. Agatensi, I. K. Ross, G. W. Emerson, R. Lorenzini, P. A. Sullivan, and A. Cassone. 1990. Evidence for a role for secreted aspartate proteinase of Candida albicans in vulvovaginal candidiasis. J. Infect. Dis. 161:1276-1283.
24. DeBernardis, F., P. Chiani, M. Ciccozzi, G. Pellegrini, T. Ceddia, G. D'Offizzi, I. Quinti, P. Sullivan, and A. Cassone. 1996. Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus. Infect. Immun. 64:466-471.
25. DeBernardis, F., A. Molinari, M. Boccanera, A. Stringaro, R. Robert, J. M. Senet, G. Arancia, and A. Cassone. 1994. Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis. Infect. Immun. 62:509-519.
26. Dembry, L. M., J. A. Vazquez, and M. J. Zervos. 1994. DNA analysis in the study of the epidemiology of nosocomial candidiasis. Infect. Control. Hosp. Epidemiol. 5:48-53.
27. Denning, D. W. 1994. Fluconazole resistance in Candida in patients with AIDS: a therapeutic approach. J. Infect. 26:117-125.
28. Diamond, R. D. 1991. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev. Infect. Dis. 13:480-486.
29. Dupont, B., and C. Drouhet. 1988. Fluconazole in the management of oropharyngeal candidiasis in a predominantly HIV antibody-positive group of patients. J. Med. Vet. Mycol. 26:67-71.
30. Edwards, J. E., Jr., G. P. Bodey, R. A. Bowden, T. Buchner, B. E. DePauw, S. G. Filler, M. A. Ghannoum, M. Glauser, R. Herbrecht, C. A. Kauffman, S. Kohno, P. Martino, F. Meunier, T. Mori, M. A. Pfaller, J. H. Rex, T. R. Rogers, R. H. Rubin, J. Solomkin, C. Viscoli, T. J. Walsh, and M. White. 1997. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin. Infect. Dis. 25:161-163.
31. Edwards, J. E., Jr. 1991. Invasive Candida infections-evolution of a fungal pathogen. N. Engl. J. Med. 324:1060-1062.
32. Ehrensaft, D. V., R. B. Epstien, S. Sarpel, and B. R. Andersen. 1979. Disseminated candidias in leukopenic dogs. Proc. Soc. Exp. Biol. Med. 160:6-10.
33. Eichel, M., G. Just-Nubling, E. B. Helm, and W. Stille. 1996. Itraconazole suspension in the treatment of HIV-infected patients suffering from fluconazole-resistant oropharyngeal and esophageal candidosis. Mycoses 39: 102-106.
34. Eisenstein, B. I., and N. C. Engleberg. 1986. Applied molecular genetics: new tools for microbiologists and clinicians. J. Infect. Dis. 153:416-430.
35. Elin, R. J., J. B. Edelin, and S. M. Wolff. 1974. Infection and immunoglobulin concentrations in Chédiak-Higashi mice. Infect. Immun. 10:88-91.
36. Fan-Havard, P., D. Capano, S. M. Smith, A. Mangia, and R. H. Eng. 1991. Development of resistance in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob. Agents Chemother. 35:2302-2305.
37. Fichtenbaum, C. J., and W. Powderly. 1998. Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 26:556-565.
38. Fidel, P. L., Jr. 1998. Unpublished observations.
39. Fidel, P. L., Jr., M. E. Lynch, and J. D. Sobel. 1993. Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect. Immun. 61:1990-1995.
40. Fidel, P. L., Jr., and J. D. Sobel. 1996. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev. 9:335-348.
41. Fidel, P. L., Jr., J. L. Cutright, L. Tait, and J. D. Sobel. 1996. A murine model of Candida glabrata vaginitis. J. Infect. Dis. 173:425-431.
42. Fidel, P. L., Jr., K. A. Ginsburg, J. L. Cutright, N. A. Wolf, D. Leaman, K. Dunlap, and J. D. Sobel. 1997. Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Thl-type responses following intravaginal challenge with Candida antigen. J. Infect. Dis. 176: 728-739.
43. Fidel, P. L., Jr., M. E. Lynch, D. H. Conaway, L. Tait, and J. D. Sobel. 1995. Mice immunized by primary vaginal C. albicans infection develop acquired vaginal mucosal immunity. Infect. Immun. 63:547-553.
44. Fidel, P. L., Jr., M. E. Lynch, V. Redondo-Lopez, J. D. Sobel, and R. Robinson. 1993. Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis (RVVC). J. Infect. Dis. 168:1458-1465.
45. Fidel, P. L., Jr., M. E. Lynch, and J. D. Sobel. 1994. Effects of pre-induced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect. Immun. 62:1032-1038.
46. Fidel, P. L., Jr., M. E. Lynch, and J. D. Sobel. 1995. Circulating CD4 and CDS T cells have little impact on host defense against experimental vaginal candidiasis. Infect. Immun. 63:2403-2408.
47. Filler, S. G., J. N. Swerdloff, C. Hobbs, and P. M. Luckett. 1995. Penetration and damage of endothelial cells by Candida albicans. Infect. Immun. 63: 976-983.
48. Fong, I. W., P. McCleary, and S. Read. 1992. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis. Am. J. Obstet. Gynecol. 166:887-890.
49. Fox, R. I., K. R. Neal, C. L. S. Leen, M. E. Ellis, and B. K. Mandal. 1991. Fluconazole resistant Candida in AIDS. J. Infect. Dis. 22:201-204.
50. Francis, P., and T. J. Walsh. 1992. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics and antifungal therapy. Clin. Infect. Dis. 15:1003-1018.
51. Fraser, V. J., J. Dunkel, S. Storfer, G. Medoff, and W. C. Dunagan. 1992. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. 15:414-421.
52. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-328.
53. Geiger, A. M., B. Foxman, and J. D. Sobel. 1995. Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, Candida glabrata, and no Candida. Genitourin. Med. 71:304-307.
54. Ghannoum, M. A., J. R. Rex, and J. N. Galgiani. 1996. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J. Clin. Microbiol. 34:489-495.
55. Graybill, J. R., J. Vazquez, R. O. Darouiche, R. Morhart, D. Greenspan, C. Tuazon, L. J. Wheat, J. Carey, I. H. R. G. Leviton, R. R. Macgregor, W. Valenti, M. Restrepo, and B. L. Moskovitz. 1998. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am. J. Med. 104:33-39.
56. Greenspan, D. 1994. Treatment of oropharyngeal candidiasis in HIV-positive patients. J. Am. Acad. Dermatol. 31:S51-S55.
57. Haley, L. D. 1961. Yeasts of medical importance. Am. J. Clin. Pathol. 36:227-234.
58. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
59. Hay, R. J. 1990. Overview of studies of fluconazole in oropharyngeal candidiasis. Rev. Infect. Dis. 12:334-337.
60. Hazen, K. C., B. J. Plotkin, and D. M. Klima. 1986. Influence of growth conditions on cell surface hydrophobicity of Candida albicans and Candida glabrata. Infect. Immun. 54:269-271.
61. Mickey, W. F., L. H. Sommerville, and F. J. Schoen. 1983. Disseminated Candida glabrata: report of a uniquely severe infection and a literature review. Am. J. Clin. Pathol. 80:724-727.
62. Reference deleted.
63. Hitchcock, C. A. 1993. Resistance of Candida albicans to azole antifungal agents. Biochem. Soc. Trans. 21:1039-1047.
64. Hitchcock, C. A., K. J. Barrett-Bee, and N. J. Russell. 1987. Inhibition of 14 α-sterol demethylase activity in Candida albicans Darlington does not correlate with resistance to azole. J. Med. Vet. Mycol. 25:329-333.
65. Hitchcock, C. A., G. W. Pye, P. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.
66. Holm, H. W., and R. M. Marwin. 1967. Effects of surface active agents on the susceptibility of Swiss mice to Candida albicans. Mycopathol. Mycol. Appl. 33:186-192.
67. Horn, R., B. Wong, T. E. Kiehn, and D. Armstrong. 1985. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev. Infect. Dis. 7:646-655.
68. Horsburgh, C. R., Jr., and C. H. Kirkpatrick. 1983. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with 21 patients. Am. J. Med. 74:23-29.
69. Hostetter, M. K. 1994. Adhesins and ligands involved in the interaction of Candida spp. with epithelial and endothelial surfaces. Clin. Microbiol. Rev. 7:29-12.
70. Howell, S. A., R. M. Anthony, and E. Power. 1996. Application of RAPD and restriction enzyme analysis to the study of oral carriage of Candida albicans. Lett. Appl. Microbiol. 22:125-128.
71. Howell, S. A., and W. C. Noble. 1990. Typing tools for the investigation of epidemic fungal infection. Epidemiol. Infect. 105:1-9.
72. Hunter, P. R., G. A. J. Harrison, and C. A. M. Fraser. 1990. Cross infection and diversity of Candida albicans strain carriage in patients and nursing staff on an intensive care unit. J. Med. Vet. Mycol. 28:317-325.
73. Ibrahim, A. S., F. Mirbod, S. G. Filler, B. Yoshiko, G. Cole, Y. Kitajima, J. E. Edwards, Jr., Y. Nosawa, and M. A. Ghannoum. 1995. Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect. Immun. 63:1993-1998.
74. Imam, N., C. C. J. Carpenter, K. H. Mayer, A. Fisher, M. Stein, and S. B. Danforth. 1990. Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am. J. Med. 89:142-146.
75. Isenberg, H. D., V. Tucci, F. Cintron, C. Singer, G. S. Weinstein, and D. Tyras. 1989. Single source outbreak of Candida tropicalis complicating coronary bypass surgery. J. Clin. Microbiol. 27:2426-2428.
76. Johnson, E. M., D. W. Warnock, J. Luker, S. R. Porter, and C. Scully. 1995. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis. J. Antimicrob. Chemother. 35:103-114.
77. Jordan, J. A. 1994. PCR identification of four medically important Candida species by using a single primer pair. J. Clin. Microbiol. 32:2962-2967.
78. Just, G., D. Steinheimer, M. Schnellbach, C. Bottinger, E. B. Helm, and W. Stille. 1989. Change of causative organisms under antifungal treatment in immunosuppressed patients with HIV infection. Mycoses 32:47-51.
79. Khattak, M. N., J. P. Burnie, R. C. Matthews, and B. A. Oppenheim. 1992. Clamped homogenous electric field gel electrophoresis typing of Torulopsis glabrata isolates causing nosocomial infections. J. Clin. Microbiol. 30:2211-2215.
80. Kikutani, H., and S. Makino. 1992. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51:285-322.
81. Kirkpatrick, C. H. 1989. Chronic mucocutaneous candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 8:448-456.
82. Kirkpatrick, C. H., R. R. Rich, and J. E. Bennett. 1971. Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann. Intern. Med. 75:955-978.
83. Kitchen, V. S., M. Savage, and J. R. Harris. 1995. Candida albicans resistance in AIDS. J. Infect. Dis. 22:204-205.
84. Klotz, S. A., D. Drutz, J. L. Harrison, and M. Huppert. 1983. Adherence and penetration of vascular endothelium by Candida yeasts. Infect. Immun. 42:374-384.
85. Klotz, S. A., D. Drutz, and J. E. Zajic. 1985. Factors governing adherence of Candida species to plastic surfaces. Infect. Immun. 50:97-101.
86. Knoke, M., K. Schulz, and H. Bernhardt. 1997. Dynamics of Candida isolations from humans from 1992-1995 in Greifswald, Germany. Mycoses 40:105-110.
87. Koletar, S. L., J. A. Russell, R. J. Fass, and J. F. Plouffe. 1990. Comparison of oral fluconazole and clotrimazole troches as treatment for oral candidiasis in patients infected with human immunodeficiency virus. Antimicrob. Agents. Chemother. 34:2267-2268.
88. Koletar, S. L., H. G. Raimundo, and M. B. Raimundo. 1994. Thrush unresponsive to treatment with fluconazole in HIV-positive patients, abstr. 35, p. 61. In Proceedings of the First National Conference on Human Retroviruses.
89. Reference deleted.
90. Komshian, S. V., A. K. Uwaydah, and J. D. Sobel. 1989. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev. Infect. Dis. 11:379-390.
91. Kwon-Chung, K. J., and J. E. Bennett. 1992. Candidiasis (moniliasis, thrush, Candida paronychia, Candida endocarditis, bronchomycosis, mycotic vulvovaginitis, candiosis), p. 280-336. In C. Cann (ed.), Medical mycology. Lea & Febiger, Philadelphia, Pa.
92. Reference deleted.
93. Law, D., C. B. Moore, and D. W. Denning. 1997. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents. Chemother. 41:2310-2311.
94. Leen, C. L. S., E. M. Dunbar, and M. E. Ellis. 1990. Once weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study. J. Infect. 21:55-60.
95. Lockhart, S. R., S. Joly, C. Pujol, J. D. Sobel, M. A. Pfaller, and D. R. Soll. 1997. Development and verification of fingerprinting probes for Candida glabrata. Microbiology 143:3733-3746.
96. Lynch, M. E., and J. D. Sobel. 1994. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J. Med. Vet. Mycol. 32:267-274.
97. Lynch, M. E., J. D. Sobel, and P. L. Fidel, Jr. 1996. Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidasis. J. Med. Vet. Mycol. 34:337-339.
98. Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:219-225.
99. Marquis, G., S. Montplaisir, M. Pelletier, S. Moussean, and P. Auger. 1986. Strain-dependent differences in susceptibility of mice to experimental candidosis. J. Infect. Dis. 154:906-909.
100. Marriot, M. S., and K. Richardson. 1987. The discovery and mode of action of fluconazole. J. R. Prous Science Publishers, Barcelona, Spain.
101. Mathur, S., G. Virella, J. Koistinen, E. O. Horger, T. A. Mahvi, and H. H. Fudenberg. 1977. Humoral immunity in vaginal candidiasis. Infect. Immun. 15:287-294.
102. Matthews, R. C., J. P. Burnie, D. Howat, T. Rowland, and F. Walton. 1991. Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunology 74:20-24.
103. Matthews, R. C., J. P. Burnie, and S. Tabaqchali. 1984. Immunoblot analysis of the serological response in systemic candidosis. Lancet ii:1415-1418.
104. Medoff, G., W. E. Dismukes, R. H. I. Meade, and J. M. Moses. 1972. A new therapeutic approach to Candida infections, a preliminary report. Arch. Intern. Med. 130:241-245.
105. Mendling, W., and U. Koldovsky. 1996. Immunological investigations in vaginal mycoses. Mycoses 39:177-183.
106. Merz, W. G. 1986. Candida albicans strain delineation. Clin. Microbiol. Rev. 3:321-334.
107. Merz, W. G., J. E. Karp, D. Schron, and R. Saral. 1986. Increased incidence of fungemia caused by Candida krusei. J. Clin. Microbiol. 24:581-584.
108. Meunier, F. M., M. Paesmans, and P. Autier. 1994. Value of antifungal prophylaxis with antifungal drugs against oropharyngeal candidiasis in cancer patients. Eur. J. Cancer 30B:196-199.
109. Miyakawa, Y., K. Kagaya, Y. Fukazawa, and S. Soe. 1986. Production and characterization of agglutinating monoclonal antibodies against predominant antigenic factors for Candida albicans. J. Clin. Microbiol. 23:881.
110. Mosman, T. R., and R. L. Coffman. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:145-173.
111. Murray, P. A., S. L. Koletar, I. Mallegol, J. Wu, and B. L. Moskovitz. 1997. Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients. Clin. Ther. 19:1-10.
112. Neuman, S. L., T. P. Flanigan, A. Fisher, M. G. Rinaldi, M. Stein, and K. Vigilante. 1994. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin. Infect. Dis. 19:684-686.
113. Nguyen, M. H., J. E. Peacock, A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
114. Nguyen, M. T., P. J. Weiss, and LaBarre. 1996. Orally administered amphotericin B in the treatment of oral candidiasis in HIV-infected patients caused by azole-resistant Candida albicans. AIDS 10:1745-1747.
115. Odds, F. C. 1988. Chronic mucocutaneous candidiosis, p. 104-110. In Candida and candidosis. University Park Press, Baltimore, Md.
116. Odds, F. C. 1988. Ecology and epidemiology of candidiasis, p. 89. In Candida and candidosis. University Park Press, Baltimore, Md.
117. Odds, F. C. 1993. Resistance to azole-derivative antifungals. J. Antimicrob. Chemother. 31:463-471.
118. Parkinson, T., D. J. Falconer, and C. A. Hitchcock. 1995. Fluconazole resistance due to energy dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. 39:1696-1699.
119. Pawlik, B., and J. Barylak. 1978. Phenotypes of resistance to fluoropyridines and the occurrence of 5-fluorocytosine-resistant mutants in Candida and Torulopsis yeast. Mykosen 21:377-381.
120. Pawlik, B., Z. Liber, and E. Jurkowska. 1989. Occurrence and the sensitivity to drugs of fungi other than Candida albicans isolated from the vagina. Med. Dosw. Mikrobiol. 41:60-66.
121. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes. Clin. Infect. Dis. 22:S89-S94.
122. Phillips, P., J. Zemcov, and W. Mahmood. 1996. Itraconazole cyclodextrin solution for fluconazole-refractory oropharyngeal candidiasis in AIDS: correlation of clinical response with in vitro susceptibility. AIDS 10:1369-1376.
123. Pons, V., D. Greenspan, and M. Debruin. 1993. Therapy for oropharyngeal candidiasis in HIV-infected patients: A randomized prospective multicenter study of oral fluconazole versus clotrimazole troches. J. Acquired Immune Defic. Syndr. 6:1311-1316.
124. Powderly, W. G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826-832.
125. Reagan, D. R., M. A. Pfaller, R. J. Hollis, and R. P. Wenzel. 1990. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J. Clin. Microbiol. 28:2733-2738.
126. Redondo-Lopez, V., M. Lynch, C. Schmitt, R. Cook, and J. D. Sobel. 1990. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet. Gynecol. 76:651-655.
127. Revankar, S. G., O. Dib, W. R. Kirkpatrick, R. K. McAtee, A. W. Fothergill, M. G. Rinaldi, S. W. Redding, and F. F. Patterson. 1998. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 26:960-963.
128. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, O. Dib, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1996. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 174:821-827.
129. Rex, J. H., M. A. Pfaller, L. A. Barry, P. W. Nelson, and C. D. Webb. 1995. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob. Agents Chemother. 39:40-44.
130. Rex. J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
131. Rex, J. H., and A. M. Sugar. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
132. Rhoads, J. L., D. C. Wright, R. R. Redfield, and D. S. Burke. 1987. Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 257:3105-3107.
133. Rivett, A. G., J. A. Perry, and J. Cohen. 1986. Urinary candidiasis: a prospective study in hospitalized patients. Urol. Res. 14:183-186.
134. Rogers, T. J., and E. Balish. 1980. Immunity to Candida albicans. Microbiol. Rev. 44:660-682.
135. Romani, L., P. Puccetti, and F. Bistoni. 1996. Biological role of Th cell subsets in candidiasis, p. 114-137. In S. Romagnani (ed.), Th1 and Th2 cells in health and diseases. Karger, Farmington, Conn.
136. Ross, I. K., F. DeBernardis, G. W. Emerson, A. Cassone, and P. A. Sullivan. 1990. The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-deficient mutant. J. Gen. Microbiol. 136:687-694.
137. Ruhnke, M., A. Schmidt-Westhausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptibility and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577.
138. Ryley, J. F., R. G. Wilson, and K. J. Barrett-Bee. 1984. Azole resistance in Candida albicans. Sabouraudia 22:53-63.
139. Sanchez, V., J. A. Vazquez, D. Barth-Jones, J. D. Sobel, and M. J. Zervos. 1993. Nosocomial acquisitions of Candida parapsilosis: an epidemiological study. Am. J. Med. 94:577-582.
140. Sanchez, V. T., J. A. Vazquez, D. Jones, L. M. Dembry, J. D. Sobel, and M. J. Zervos. 1992. Epidemiology of nosocomial infection with Candida lusitaniae. J. Clin. Microbiol. 30:3005-3008.
141. Sangeorzan, J. A., S. F. Bradley, X. He, L. T. Zarins, G. L. Ridenour, R. N. Tiballli, and C. A. Kauffman. 1994. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am. J. Med. 97:339-346.
142. Schuman, P., L. Capps, and G. Peng. 1997. Weekly fluconazole for the treatment of mucosal candidiasis in women with HIV infection. A randomized, double blind, placebo controlled trial. Ann. Intern. Med. 126:689-696.
143. Schuman, P., J. D. Sobel, S. Ohmit, K. H. Mayer, A. Rompalo, A. Duerr, D. K. Smith, D. Warren, and R. S. Klein. Mucosal Candida colonization and candidiasis in women with or without at-risk for HIV infection. Clin. Infect. Dis., in press.
144. Schwab, U., F. Chernomas, L. Larcom, and J. Weems. 1997. Molecular typing and fluconazole susceptibility of urinary Candida glabrata isolates hospitalized patients. Diagn. Microbiol. Infect. Dis. 29:11-17.
145. Shadomy, S., C. B. Kirchoff, and A. Espinel-Ingroff. 1973. In vitro activity of 5-fluorocytosine against Candida and Tomlopxis species. Antimicrob. Agents Chemother. 3:9-14.
146. Shakir, B. S., M. V. Martin, and C. J. Smith. 1983. Relative effectiveness of various yeasts, Candida spp. and Torulopsis glabrata, for inducing palatal infection in the Wistar rat. Arch. Oral Biol. 28:1069-1071.
147. Shepherd, M. G., R. T. M. Poulter, and P. A. Sullivan. 1985. Candida albicans: biology, genetics, and pathogenicity. Annu. Rev. Microbiol. 39: 579-614.
148. Silverman, S. J., W. Gallo, M. L. McKnight, P. Mayer, S. deSanz, and M. Tan. 1996. Clinical characteristics and management responses in 85 HIV-infected patients with oral candidiasis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 82:402-407.
149. Sinnott, J. T., IV. 1987. Candida (Torulopsis) glabrata. Infect. Control. 8:334-336.
150. Sobel, J. D. 1988. Pathogenesis and epidemiology of vulvovaginal candidiasis. Ann. N. Y. Acad. Sci. 544:547-557.
151. Sobel, J. D. 1998. Unpublished observations.
152. Sobel, J. D., and W. Chaim. 1997. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. Clin. Infect. Dis. 24:649-652.
153. Sobel, J. D., S. Faro, R. Force, B. Foxman, W. J. Ledger, P. R. Nyirjesy, B. D. Reed, and P. R. Summers. 1998. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol. 178:203-211.
154. Sobel, J. D., C. A. Kaufman, D. McKinsey, and M. Zervos. Candiduria - a randomized, double-blind study of treatment with fluconazole. Submitted for publication.
155. Sobel, J. D., G. Muller, and H. R. Buckley. 1984. Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect. Immun. 44:576-580.
156. Soll, D. R. 1988. High frequency switching in Candida albicans and its relations to vaginal candidiasis. Am. J. Obstet. Gynecol. 158:997-1001.
157. Soll, D. R. 1992. High-frequency switching in Candida albicans. Clin. Microbiol. Rev. 5:183-203.
158. Soll, D. R. 1998. Unpublished observations.
159. Soll, D. R., R. Galask, S. Isley, et al. 1989. Switching of Candida albicans during successive episodes of recurrent vaginitis. J. Clin. Microbiol. 27:681-690.
160. Spinillo, A., E. Capuzzo, T. Egbe, F. Baltaro, S. Nicola, and G. Piazzi. 1995. Torulopsis glabrata vaginitis. Obstet. Gynecol. 85:993-998.
161. Steele, C., H. Ozenci, W. Luo, M. Scott, and P. L. Fidel Jr. Growth inhibition of Candida albicans by vaginal cells from native mice. Submitted for publication.
162. Steffan, P., D. Boikov, C. Xu, J. D. Sobel, R. A. Akins, and J. A. Vazquez. 1997. Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates. J. Clin. Microbiol. 35:2031-2039.
163. Stenderup, A. 1990. Oral mycology. Acta Odontol. Scand. 48:3-10.
164. Stenderup, A., and G. T. Pederson. 1962. Yeasts of human origin. Acta Pathol. Microbiol. Scand. 54:462-472.
165. Stenderup, A., and H. Schonheyder. 1984. Mycoses complicating AIDS. Microbiol. Sci. 1:219-223.
166. Vanden-Bossche, H., D. W. Warnock, and B. Dupont. 1994. Mechanisms and clinical impact of antifungal resistance. J. Med. Vet. Mycol. 32:189-202.
167. Vanden-Bossche, H., P. Marichal, F. C. Odds, L. LeJeune, and M. C. Coene. 1992. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 36:2602-2610.
168. Reference deleted.
169. Vazquez, J. 1998. Unpublished observations.
170. Vazquez, J. A., A. Beckley, J. D. Sobel, and M. J. Zervos. 1991. Comparison of restriction enzyme analysis versus pulse-field gradient gel electrophoresis as a typing system for Candida albicans. J. Clin. Microbiol. 29:962-967.
171. Vazquez, J. A., L. M. Dembry, V. Sanchez, M. A. Vazquez, J. D. Sobel, C. Dmuchowski, and M. J. Zervos. 1998. Nosocomial Candida glabrata colonization: an epidemiologic study. J. Clin. Microbiol. 36:421-426.
172. Vazquez, J. A., C. Kauffman, J. D. Sobel, M. B. Perri, and M. J. Zervos. 1991. A comparative study of in vitro susceptibility of Candida species, p. 178. In Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
173. Vazquez, J. A., C. Sanchez, C. Dmuchowski, L. Dembry, J. D. Sobel, and M. J. Zervos. 1993. Nosocomial acquisition of Candida albicans: an epidemiologic study. J. Infect. Dis. 168:195-201.
174. Vazquez, J. A., and J. D. Sobel. 1997. Epidemiologic overview of resistance to oral antifungal agents in the immunocompromised host. Excerpta. Med. Int. Congr. Ser. 1997:1-11.
175. Warnock, D., J. Burke, N. J. Cope, E. Johnson, N. Von Fraunhoffer, and E. Williams. 1988. Fluconazole resistance in Candida glabrata. Lancet ii:1310. (Letter.)
176. Wey, S. B., M. Motomi, M. A. Pfaller, R. F. Wolsen, and R. P. Wenzel. 1989. Risk factors for hospital-acquired candidemia: a matched case control study. Arch. Intern. Med. 149:2249-2253.
177. Whelan, W. L., S. Simon, E. S. Beneke, and A. L. Rogers. 1984. Auxotrophic variants of Torulopsis glabrata. FEMS Microbiol. Lett. 24:1-4.
178. White, M. H. 1996. Is vulvovaginal candidiasis an AIDS-related illness. Clin. Infect. Dis. 22(Suppl. 2):S124-S127.
179. Wilcox, C. M., R. O. Darouiche, L. Laine, B. L. Moskovitz, I. Mallegol, and J. Wu. 1997. A randomized double-blind comparison of itraconazole oral solution and fluconazole tablets in the treatment of esophageal candidiasis. J. Infect. Dis. 176:227-232.
180. Willocks, L., C. L. Leen, R. P. Brettle, D. Urquhart, T. B. Russell, and L. J. Milne. 1991. Fluconazole resistance in AIDS patients. Antimicrob. Agents Chemother. 28:939.
181. Wingard, J., W. Merz, and R. Saral. 1979. Candida tropicalis: a major pathogen in immunocompromised patients. Ann. Intern. Med. 91:529-543.
182. Wingard, J. R. 1994. Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy. Clin. Infect. Dis. 19:S49-S53.
183. Wingard, J. R. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.
184. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 18:1274-1277.
185. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.
186. Wise, G. J., and D. A. Silver. 1993. Fungal infections of the genitourinary system. J. Urol. 149:1377-1388.